v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:        
Total revenue $ (1,474) $ 1,348 $ 2,264 $ 4,088
Operating costs and expenses:        
Cost of goods sold $ 2 $ 85 $ 4,108 $ 337
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 6,821 $ 5,865 $ 14,387 $ 15,040
Selling, general and administrative 9,266 7,057 15,128 15,164
Restructuring charge 11 393 33 519
Total operating costs and expenses 16,100 13,400 33,656 31,060
Loss from operations (17,574) (12,052) (31,392) (26,972)
Interest and other, net        
Interest expense (2,368) (2,009) (4,795) (4,265)
Gain on deconsolidation of subsidiary 30,940 0 30,940 0
Interest income and other income (expenses), net 975 286 2,088 698
Total interest and other, net 29,547 (1,723) 28,233 (3,567)
Income (loss) from continuing operations before income taxes 11,973 (13,775) (3,159) (30,539)
Benefit from income taxes (1) (92) (1) (90)
Income (loss) from continuing operations 11,974 (13,683) (3,158) (30,449)
Income (loss) from discontinued operations, net of tax (0) 6,080 (66) 27,485
Net income (loss) $ 11,974 $ (7,603) $ (3,224) $ (2,964)
Income (loss) from continuing operations per share - basic $ 2.96 $ (3.38) $ (0.78) $ (7.54)
Income (loss) from continuing operations per share - diluted 2.96 (3.38) (0.78) (7.54)
Income (loss) from discontinued operations per share - basic (0) 1.5 (0.02) 6.81
Income (loss) from discontinued operations per share - diluted (0) 1.5 (0.02) 6.81
Net income (loss) per share - basic 2.96 (1.88) (0.8) (0.73)
Net income (loss) per share - diluted $ 2.96 $ (1.88) $ (0.8) $ (0.73)
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 4,048 4,042 4,048 4,040
Diluted 4,048 4,042 4,048 4,040
Development and Other Revenue [Member]        
Revenue:        
Total revenue $ 103 $ 133 $ 349 $ 277
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ (1,577) $ 1,215 $ 1,915 $ 3,811